Salanersen, a treatment candidate for spinal muscular atrophy (SMA) now in clinical testing, is safe and was shown to stabilize or improve motor function over at least one year of follow-up in ...

Columnist Ari Anderson recently enjoyed six weeks free from searching for new members of his nursing staff. Now, he's aiming ...

Mutations that cause spinal muscular atrophy (SMA) may lead to abnormalities in the development of cells in the spinal cord, a study found.

SMA newborn screening may help infants start treatment sooner, which researchers say could support better motor development outcomes.

Columnist Helen Baldwin has always been drawn to caring for those who need a little extra help, be it a shelter dog or a baby with SMA.

Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases.

Apitegromab improved motor function in SMA patients in a Phase 3 trial analysis, with stronger benefits seen in those treated earlier.